Aligos Therapeutics, Inc. (ALGS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US01626L2043
Aligos Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.19 m USD |
| Operating income | -87.99 m USD |
| EBIT | -23.88 m USD |
| Net income | -24.19 m USD |
| Diluted EPS – continuing operations | -2.45 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
More stocks
- Passage BIO, Inc. (PASG)
- American Strategic Investment Co. (NYC)
- EON Resources Inc. (EONR)
- ACCESS Newswire Inc. (ACCS)
- Foreveren (FOR.WA)
- TerraVolt Holdings, Inc. (GEDC)
- DYADIC INTERNATIONAL INC (DYAI)
- Jasper Therapeutics, Inc. (JSPR)
- BARFRESH FOOD GROUP INC. (BRFH)
- Bridger Aerospace Group Holdings, Inc. (BAER)
- SUNation Energy, Inc. (SUNE)
- Fold Holdings, Inc. (FLD)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.